You are here: Industry Insights > Takeda

News List

Takeda to sell assets in Asia Pacific to Celltrion for $266m pharmaceutical-technology
June 15, 2020
Takeda Pharmaceutical has signed an agreement to sell certain non-core over-the-counter (OTC) and prescription pharmaceutical assets available only in the Asia Pacific to South Korean biopharmaceutical firm Celltrion for $266m in an upfront payment.
US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer pharmaceutical-business-review
May 28, 2020
Takeda Pharmaceutical Company announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) ...
New US approval for Takeda’s Alunbrig pharmatimes
May 26, 2020
US regulators have expanded the scope of Takeda's Alunbrig (brigatinib) to include first-line treatment of adults with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
EU regulators approve Takeda's Adcetris for sALCL pharmatimes
May 15, 2020
European regulators have approved Takeda's Adcetris (brentuximab vedotin) for use in adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) in combination with CHP (cyclophosphamide, doxorubicin, prednisone).
Takeda offloads $670M of European drugs as consumer health sale rumors resurface fiercepharma
April 26, 2020
Takeda has inked yet another deal aimed at lowering its debt level after the Shire acquisition.The Japanese pharma said Friday that is has agreed to sell about 110 over-the-counter and prescription drugs in Europe, as well as two manufacturing sites, to D
Takeda to sell OTC and non-core assets to Orifarm for $670m pharmaceutical-technology
April 26, 2020
Takeda Pharmaceutical has signed an agreement to sell around 110 of its non-core over-the-counter (OTC) and prescription pharmaceutical products to Danish pharmaceutical firm Orifarm Group for $670m.
ProThera, Takeda Enter Anti-Inflammatory Alliance contractpharma
April 24, 2020
To develop a novel plasma-derived Inter-alpha Inhibitor Proteins therapy for the treatment of acute inflammatory conditions.
Takeda, CSL-led plasma players band together on COVID-19 fiercebiotech
April 13, 2020
There’s more than one way to skin a cat. And in the race to create a plasma-based treatment for COVID-19, industry leaders have decided the best way is to join forces.
Expanded EU approval for Takeda's Alunbrig pharmatimes
April 10, 2020
European regulators have expanded the scope of Alunbrig (brigatinib) to include its use as a monotherapy for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) ...
Expanded EU approval for Takeda's Alunbrig pharmatimes
April 08, 2020
European regulators have expanded the scope of Alunbrig (brigatinib) to include its use as a monotherapy for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page